Claims
- 1. A compound having the structure:
- 2. The compound of claim 1, wherein one or more of RA—RC comprise one or more phosphorus moieties each independently a group having a structure from Series I below:
- 3. The compound of claim 1, wherein RB is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety substituted with at least one of the phosphorus-containing moieties in Series I depicted below:
- 4. The compound of claim 1, wherein RC is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety substituted with at least one of the phosphorus-containing moieties in Series I depicted below:
- 5. The compound of claim 1, wherein RA is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety substituted with at least one of the phosphorus-containing moieties in Series I depicted below:
- 6. The compound of claim 1, wherein any one or more of RA—RC comprises a phosphorus-containing moiety of Series Ia:
- 7. The compound of claim 6, wherein R1 is H or lower alkyl; M is —CH2—, —CH(OH)—, —CH(halo)-, or C(halo)2-; R6 is lower alkyl and R is H.
- 8. The compound of claim 1, wherein any one or more of RA—RC comprises a phosphorus-containing moiety of Series Ib:
- 9. The compound of claim 1, wherein any one or more of RA—RC comprises a phosphorus-containing moiety of Series Ic:
- 10. The compound of claim 1, wherein any one of RA—RC, comprises any one of the phosphorus-containing aryl of heteroaryl moieties of Series II:
- 11. The compound of claim 10, wherein m is 0, x is 1 and PCM is —P(O)(R1)2.
- 12. The compound of claim 1, wherein any one of RA—RC, comprises any one of the phosphorus-containing aryl or heteroaryl moieties of Series IIa.
- 13. The compound of claim 12, wherein PCM is —P(O)(R1)2.
- 14. The compound of claim 1, wherein any one of RA—RC, comprises any one of the phosphorus-containing aryl or heteroaryl moieties of Series IIb:
- 15. The compound of claim 14, wherein the phosphorus-containing moiety has the structure:
- 16. The compound of claim 1, wherein any one of RA—RC, comprises any one of the phosphorus-containing aryl or heteroaryl moieties of Series III:
- 17. The compound of claim 2, wherein Y is a chemical bond linking the phosphorus atom to R1.
- 18. The compound of claim 2, wherein Y is an oxygen atom.
- 19. The compound of claim 2, wherein Y is a chemical bond linking the phosphorus atom to R1 and R1 is an alkyl group having 1-6 carbon atoms.
- 20. The compound of claim 1, wherein RA is an aryl, heteroaryl, alkylaryl, or alkylheteroaryl group:
- 21. The compound of claim 20, wherein PCM is a moiety —P(O)(R1)2.
- 22. The compound of claim 20, wherein AR is a substituted or unsubstituted aryl moiety other than phenyl, is a substituted heteroaryl moiety, or is a substituted or unsubstituted alkylaryl or alkylheteroaryl moiety.
- 23. The compound of claim 20, wherein RB is a substituted or unsubstituted aryl or alkylaryl moiety other than phenyl or alkylphenyl, or is a substituted heteroaryl moiety.
- 24. The compound of claim 20, wherein AR or RB is either substituted-pyridyl or substituted pyrimidine.
- 25. The compound of claim 1, wherein RA is a substituted or unsubstituted aliphatic or heteroaliphatic moiety AL:
- 26. The compound of claim 25, wherein PCM is a moiety —P(O)(R1)2.
- 27. The compound of claim 25, wherein AL is a substituted or unsubstituted, cyclic or acyclic, linear or branched heteroaliphatic moiety, or is a substituted or unsubstituted cyclic aliphatic moiety, or is a substituted or unsubstituted, linear or branched alkyl moiety having greater than 10 carbon atoms.
- 28. The compound of claim 25, wherein AL is substituted or unsubstituted, linear or branched, cyclic or acyclic aliphatic or heteroaliphatic moiety other than linear C1-10alkyl.
- 29. The compound of claim 25, wherein RB or RC comprises a phosphorus-containing moiety of Series II.
- 30. The compound of claim 25, wherein RB or RC comprises a phosphorus-containing moiety of Series IIa:
- 31. The compound of claim 25, wherein RB or RC comprises a phosphorus-containing moiety of Series IIb:
- 32. The compound of claim 25, wherein RB is a pyridyl moiety of Series IIa.
- 33. The compound of claim 25, wherein if RB is a pyridyl moiety of Series Ia, then either RC is not a substituted or unsubstituted C1-6 alkyl, or RA is not a phenyl moiety substituted with two occurrences of C1-6 alkyl or halogen, or a combination of the two.
- 34. The compound of claim 25, wherein RB is a pyrimidine moiety of Series IIa.
- 35. The compound of claim 1, having the structure
- 36. The compound of claim 35, wherein PCM comprises one or more of the following phosphorus-containing moieties of Series Ia:
- 37. The compound of claim 35, wherein PCM comprises one or more of the following phosphorus-containing moieties of Series Ib:
- 38. The compound of claim 1, having the structure:
- 39. The compound of claim 38, wherein PCM comprises one or more of the following phosphorus-containing moieties of Series Ia:
- 40. The compound of claim 38, wherein PCM comprises one or more of the phosphorus-containing moieties of Series Ib:
- 41. A compound having the formula:
- 42. The compound of claim 41, wherein Y is a bond linking R1 to P, and R1 is lower alkyl or aryl.
- 43. A compound having the formula:
- 44. The compound of claim 43, wherein RA is a moiety other than phenyl.
- 45. The compound of claim 43, wherein Y is a bond linking R1 to P, and R1 is lower alkyl or aryl.
- 46. A compound having the formula:
- 47. The compound of claim 46, wherein RA is a moiety other than phenyl.
- 48. The compound of claim 46, wherein Y is a bond linking R1 to P, and R1 is lower alkyl or aryl.
- 49. A compound having the formula:
- 50. The compound of claim 49, wherein Y is a bond linking R1 to P, and R1 is lower alkyl or aryl.
- 51. A compound having the formula:
- 52. The compound of claim 51, wherein Y is a bond linking R1 to P, and R1 is lower alkyl or aryl.
- 53. A pharmaceutical composition comprising any one of the compounds of claim 1, 2, 20, 25, 35, 38, 41, 43, 46, 49 or 51, or a pharmaceutically acceptable derivative thereof; and
a pharmaceutically acceptable carrier or diluent, said composition optionally further comprising an additional therapeutic agent.
- 54. The composition of claim 53, wherein the composition further comprises an additional therapeutic agent and the therapeutic agent is an anticancer agent, an antiproliferative agent, an approved agent for the treatment of osteoporosis, or an approved agent for the treatment of disorders related to increased vascular permeability.
- 55. A method for treating a bone-related disorder comprising administering a therapeutically effective amount of any one of compounds 1, 2, 20, 25, 35, 38, 41, 43, 46, 49 or 51, or a pharmaceutically acceptable derivative thereof, to a subject in need thereof,
and optionally further comprising administering an additional therapeutic agent.
- 56. A method for treating a proliferative disorder comprising administering a therapeutically effective amount of any one of compounds 1, 2, 20, 25, 35, 38, 41, 43, 46, 49 or 51, or a pharmaceutically acceptable derivative thereof, to a subject in need thereof,
and optionally further comprising administering an additional therapeutic agent.
- 57. The method of claim 56, wherein the proliferative disorder is cancer.
- 58. The method of claim 56, wherein the method further comprises administering a cytotoxic agent to a subject.
- 59. The method of claim 58, wherein the cytotoxic agent is an anticancer agent.
- 60. A method for the treatment and prophylaxis of diseases which are mediated by a kinase inhibited by a compound of any of claims 1, 2, 20, 25, 35, 38, 41, 43, 46, 49 or 51, comprising
administering a therapeutically effective amount of any one of the compounds, or a pharmaceutically acceptable derivative thereof, to a subject in need thereof.
PRIORITY INFORMATION
[0001] The present application claims priority under 35 U.S.C. § 119 to U.S. provisional application No. 60/299,920, filed Jun. 21, 2001, entitled “Novel Pyridopyrimidones and Uses Thereof”, the entire contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60299920 |
Jun 2001 |
US |